Patrik Renblad
Director of Finance/CFO chez CANTARGIA AB
Profil
Patrik Renblad is currently the Chief Financial Officer at Cantargia AB since 2023.
Prior to this, he was the Chief Financial Officer at SynAct Pharma AB from 2022 to 2023.
He also worked as a Finance Director-R&D at LEO Pharma A.
Mr. Renblad is a graduate of the University of Lund.
Postes actifs de Patrik Renblad
| Sociétés | Poste | Début |
|---|---|---|
| CANTARGIA AB | Director of Finance/CFO | 15/06/2023 |
Anciens postes connus de Patrik Renblad
| Sociétés | Poste | Fin |
|---|---|---|
| SYNACT PHARMA AB | Director of Finance/CFO | 15/05/2023 |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
Formation de Patrik Renblad
| University of Lund | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CANTARGIA AB | Health Technology |
| SYNACT PHARMA AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
